De Novo Metabolic Syndrome in Liver Transplant Patients After Immunosuppression Withdrawal
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 92
- 试验地点
- 1
- 主要终点
- relation between MS development and IS in LT recipients
研究概览
简要总结
Evaluate de novo onset of metabolic syndrome, NAFLD and NASH in liver transplant recipients who have discontinued immunosuppressive therapy ("tolerant") and in those taking immunosuppressive therapy ("non-tolerant").
详细描述
A retrospective single-center study was conducted aiming to define the incidence of de novo Metabolic Syndrome (MS) in patients who withdraw Immunosoppression (IS) drugs after Liver Transplant (Tolerant-group) compared to these who couldn't wean IS drugs(non-TOL-group).
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 49 Years 至 89 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •single LT recipients with an attempt of IS withdrawal
- •minimum 5 years follow-up
排除标准
- •Liver transplant combined with other organs
- •Presence of metabolic syndrome and/or NASH and/or NAFLD as an indication for liver transplantation
- •Loss of patient to follow-up
研究组 & 干预措施
tolerant
patients who withdraw IS drugs after LT
干预措施: Immunosuppressive (Drug)
non tolerant
patients who couldn't wean IS drugs
干预措施: Immunosuppressive (Drug)
结局指标
主要结局
relation between MS development and IS in LT recipients
时间窗: 5 years
Evaluate the de novo onset of metabolic syndrome, NAFLD and NASH in liver transplant recipients who have discontinued immunosuppressive therapy ("tolerant") and in those who could not withdraw IS ("non-tolerant").
次要结局
- IS withdrawal in LT recipients(5 years)
研究者
Roberta Angelico
Professor
University of Rome Tor Vergata